Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BSAP/PAX5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BSAP/PAX5 Recombinant Protein (Wild Type & DNA-Binding Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View PAX5 Products |
| Gene Delivery | BSAP/PAX5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and transcriptional assays. |
View PAX5 Products |
| Benchmark Ab | Anti-BSAP/PAX5 Recombinant Antibody Recombinant positive control for IHC, Flow Cytometry, and Western Blot. |
View PAX5 Products |
| Validator | BSAP/PAX5 siRNA Set For target knockdown and specificity validation. |
View PAX5 Products |
| Related Target A | IKZF1 (Ikaros) Synergistic transcription factor co-mutated with PAX5 in B-cell acute lymphoblastic leukemia (B-ALL). |
View IKZF1 Products |
| Related Target B | CD19 Direct downstream transcriptional target of PAX5; critical marker for B-cell lineage commitment. |
View CD19 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DNA-Binding Domain (DBD) Activity Validation | Sequence-verified paired domain (PD) proteins available with high purity (>95%) for EMSA and AlphaScreen assays. |
| PAX5 Homology Counter-Screening (Off-target risk) | Homolog panel proteins (PAX2, PAX8) strictly verified by mass spectrometry to ensure screening selectivity. |
| Lack of Reliable Positive Controls | Recombinant sequence-verified monoclonal benchmark antibodies included. |
| False Positive Transcription Signals | Sequence-specific siRNA pools included for functional knockdown verification. |
Live BSAP/PAX5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BSAP/PAX5 therapeutics is intensifying, with major players shifting focus from traditional diagnostic monoclonal antibodies to targeted small molecule inhibitors, PROTACs, and peptide-MHC (pMHC) immunotherapies. As first-generation direct transcription factor inhibitors reach preclinical validation, the next wave of R&D is targeting oncogenic fusion proteins (such as PAX5-JAK2) and downstream transcriptional networks to bypass resistance mechanisms in refractory B-cell malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Oncology Biotechs | B-ALL, DLBCL | DNA-Binding Inhibition Assay (Need high-purity paired domain recombinant protein) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory B-cell Malignancies | Degradation Kinetic Validation (Need Lentivirus for stable cell line construction) |
| TCR-like mAbs (pMHC) | Immunotherapy Biotechs | B-ALL (Pediatric & Adult) | Peptide-MHC binding specificity (Need high-purity HLA-complexed reference controls) |